News

xFOREST Announces Receipt of Milestone Payment from Kyowa Kirin

xFOREST Therapeutics Co., Ltd. (Headquarters: Kamigyo-ku, Kyoto, Japan; President and CEO: Shunichi Kashida; hereinafter, xFOREST) announced that it has received a milestone payment from Kyowa Kirin Co., Ltd. (Headquarters: Chiyoda-ku, Tokyo, Japan; President and CEO: Masashi Miyamoto; hereinafter, Kyowa Kirin) following the progress achieved in Kyowa Kirin’s RNA-targeted drug discovery project.

xFOREST’s proprietary large-scale biochemical analysis platform suite, "FOREST technologies," enables not only the precise identification of hit compounds but also the analysis of their interactions with target RNA structures at the single-nucleotide level and their binding selectivity profiles. This milestone marks a significant advancement in Kyowa Kirin's exploratory research for RNA-targeted therapeutics, leveraging the research outcomes enabled by xFOREST's cutting-edge technologies.

Shunichi Kashida, President and CEO of xFOREST, commented:
"We are delighted that our foundational technologies have contributed to the progress of Kyowa Kirin’s drug discovery and development efforts. Moving forward, we will continue to expand our technology base, specializing in RNA-targeted drug discovery, to support processes beyond hit identification. By doing so, we aim to accelerate the development of innovative new medicines."

This milestone achievement underscores the potential of xFOREST’s technologies in advancing RNA-targeted drug discovery and signals continued collaboration to drive innovation in pharmaceutical research and development.